Filing Flows › Ironwood Pharmaceuticals (IRWD) › Q2 2026 › vs Q1 2026
Ironwood Pharmaceuticals (IRWD) Q2 2026 vs Q1 2026 (quarter over quarter)
Ironwood Pharmaceuticals's revenue rose $6.5M (+6%) from $107M in Q1 2026 to $113M in Q2 2026. Operating margin 70.2% against 68.1% (+2.0 pts).
Ironwood Pharmaceuticals, Q2 2026: revenue $113M (+33% year over year), operating margin 70.2%, net earnings $51.3M, operating cash flow $58.3M. The chart draws each line against Q1 2026, the increases inside each band.
Margins
| Q2 2026 | Q1 2026 | Change | |
|---|---|---|---|
| Operating margin | 70.2% | 68.1% | +2.0 pts |
| Net margin | 45.4% | 38.3% | +7.1 pts |
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $113M | $107M | $6.5M | +6% |
| Operating profit | $79.3M | $72.6M | $6.7M | +9% |
| Costs & expenses | $33.7M | $33.9M | −$199K | -0.6% |
| Pre-tax earnings | $73.7M | $65.2M | $8.6M | +13% |
| Other expense, net | $5.6M | $7.4M | −$1.8M | -25% |
| Research & development | $22.4M | $21.9M | $481K | +2% |
| SG&A | $11.3M | $12.0M | −$720K | -6% |
| Net earnings | $51.3M | $40.8M | $10.5M | +26% |
| Income tax | $22.4M | $24.4M | −$2.0M | -8% |
| Depreciation | $457K | $443K | $14K | +3% |
| Share-based compensation | $3.2M | $3.7M | −$417K | -11% |
| Working capital & other | $3.3M | −$39.7M | $43.0M | — |
| Operating cash flow | $58.3M | $5.1M | $53.2M | 11× |
Questions
How much did Ironwood Pharmaceuticals's revenue grow quarter over quarter in Q2 2026?
Ironwood Pharmaceuticals's revenue rose $6.5M (+6%) from $107M in Q1 2026 to $113M in Q2 2026. Operating margin 70.2% against 68.1% (+2.0 pts).